Steatorrhoea complicating post-infectious diarrhoea in a renal transplant patient on mycophenolate mofetil therapy.
Mycophenolate mofetil (MMF) is licensed as a prophylaxis in combination therapy to prevent renal transplant rejection. Gastrointestinal side effects are fairly common and include diarrhoea, abdominal discomfort, nausea, vomiting, gastritis and constipation. This drug has recently been described as causing villous atrophy, nutrient malabsorption and colonic mucosal changes. We present a case of reversible steatorrhoea occurring in a patient treated with MMF following an episode of infections diarrhoea.
Tagboto
Senyo
S
Department of Nephrology, The Royal Infirmary, University Hospital of North Staffordshire, Stoke on Trent, Staffordshire, ST4 6QG, UK. Senyo.Tagboto@uhns.nhs.uk.
Akhtar
Farman
F
Waterford Regional Hospital, Waterford, Ireland.
D002169:Campylobacter Infections / Q000150:complications; D003967:Diarrhea / Q000209:etiology* / Q000382:microbiology; D006084:Graft Rejection / Q000628:therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D016030:Kidney Transplantation; D008286:Malabsorption Syndromes / Q000209:etiology; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000009:adverse effects / Q000031:analogs & derivatives*; D045602:Steatorrhea / Q000209:etiology*
D007166:Immunosuppressive Agents; D009173:Mycophenolic Acid